Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis

Yves Decrem, Géraldine Rath, Virginie Blasioli, Philippe Cauchie, Séverine Robert, Jérôme Beaufays, Jean Marie Frère, Olivier Feron, Jean Michel Dogné, Chantal Dessy, Luc Vanhamme, Edmond Godfroid

Résultats de recherche: Contribution à un journal/une revueArticle

5 Téléchargements (Pure)


Blood coagulation starts immediately after damage to the vascular endothelium. This system is essential for minimizing blood loss from an injured blood vessel but also contributes to vascular thrombosis. Although it has long been thought that the intrinsic coagulation pathway is not important for clotting in vivo, recent data obtained with genetically altered mice indicate that contact phase proteins seem to be essential for thrombus formation. We show that recombinant Ixodes ricinus contact phase inhibitor (Ir-CPI), a Kunitztype protein expressed by the salivary glands of the tick Ixodes ricinus, specifically interacts with activated human contact phase factors (FXIIa, FXIa, and kallikrein) and prolongs the activated partial thromboplastin time (aPTT) in vitro. The effects of Ir-CPI were also examined in vivo using both venous and arterial thrombosis models. Intravenous administration of Ir-CPI in rats and mice caused a dose-dependent reduction in venous thrombus formation and revealed a defect in the formation of arterial occlusive thrombi. Moreover, mice injected with Ir-CPI are protected against collagen- and epinephrine-induced thromboembolism. Remarkably, the effective antithrombotic dose of Ir-CPI did not promote bleeding or impair blood coagulation parameters. To conclude, our results show that a contact phase inhibitor is an effective and safe antithrombotic agent in vivo.

langue originaleAnglais
Pages (de - à)2381-2395
Nombre de pages15
journalJournal of Experimental Medicine
Numéro de publication11
Les DOIs
étatPublié - 26 oct. 2009

    Empreinte digitale

Contient cette citation